What Are Infusions for Lupus and How Do They Work?

Infusions for lupus are intravenous medications delivered directly into a vein, typically at a clinic or hospital, to suppress the overactive immune system that drives systemic lupus erythematosus (SLE). The most common options include belimumab, anifrolumab, rituximab, and cyclophosphamide, each targeting a different part of the immune response. Which infusion you receive depends on how severe your lupus is, which organs are affected, and how you have responded to oral medications.

Why Infusions Instead of Pills

Most people with lupus start on oral medications like hydroxychloroquine, anti-inflammatories, or low-dose steroids. Infusions typically enter the picture when those drugs are not enough to control the disease, when a major organ like the kidney is involved, or when steroid doses need to come down. Delivering a drug intravenously lets it reach full concentration in the blood almost immediately, and it also ensures adherence in a way that daily pills cannot: you show up, sit in a chair, and the medication goes in under medical supervision. For biologic drugs that are large protein molecules, the IV route can also be more efficient than oral delivery, since these proteins would be destroyed in the digestive tract.

Physicians also weigh practical factors when choosing between an infusion and a subcutaneous (under-the-skin) injection, which is available for some of these drugs. Doctors overwhelmingly recommend the subcutaneous option for patients who live far from an infusion center or who prefer self-administration at home.¹ If you are near a center and your doctor wants to monitor you closely, the infusion chair has its advantages.

Belimumab, the First Biologic Approved for Lupus

Belimumab (brand name Benlysta) was approved in 2011 and remains the most widely used biologic infusion for SLE. It works by blocking a protein called BLyS (also known as BAFF) that helps certain immune cells, called B cells, survive and multiply. In lupus, B cells produce the autoantibodies that attack your own tissues. By cutting off the survival signal, belimumab reduces the number and activity of those harmful B cells over time.²

The standard IV dose is given every two weeks for the first three infusions and then once a month. Each session runs about an hour. Across multiple large trials, about a third more patients on belimumab showed meaningful improvement in disease activity compared to those on placebo, based on high-certainty evidence from four randomized controlled trials.² That may not sound dramatic, but for a disease as stubborn as lupus, a consistent advantage over standard therapy is significant.

Beyond disease-activity scores, belimumab has a meaningful steroid-sparing effect, which matters because long-term steroid use causes bone loss, weight gain, diabetes, and other problems. In one real-world observational study, the median prednisone dose dropped from 10 mg per day to 5 mg by month 12, and the proportion of patients who could stop prednisone entirely continued to climb through two years of treatment.³ A scoping review of randomized trials confirmed that belimumab and anifrolumab both demonstrate clear steroid-sparing benefits.⁴ Belimumab has also been linked to improvements in fatigue and overall quality of life.⁵

Anifrolumab, Targeting the Interferon Pathway

Anifrolumab (Saphnelo) was approved in 2021 and attacks the disease from a different angle. Instead of targeting B cells directly, it blocks the type I interferon receptor. Interferons are signaling proteins that normally help the body fight viruses, but in most people with lupus, this interferon pathway is stuck in overdrive, fueling inflammation in the skin, joints, and other organs.⁶ By blocking the receptor, anifrolumab turns down that alarm signal.

Anifrolumab is given as a 30-minute IV infusion every four weeks. It tends to be particularly effective for skin and joint symptoms. Like belimumab, it also helps patients reduce steroid doses.⁴ One practical difference: your doctor may check whether you have a high “interferon signature” in blood tests before prescribing it, since patients with strong interferon activity tend to respond best.

Rituximab for Severe and Refractory Disease

Rituximab (Rituxan) is not officially approved for lupus in most countries, but rheumatologists have been using it off-label for years in patients whose disease resists standard therapies. It works by directly destroying B cells that carry a surface marker called CD20. The effect is potent: in a systematic review of 188 patients with refractory SLE treated with rituximab, 91% showed significant improvement in at least one disease manifestation. Among the 103 patients who had lupus nephritis (kidney involvement), the response rate for renal disease was also 91%.⁷

Those numbers come with a caveat. These were patients whose doctors felt strongly enough about rituximab to use it off-label, often in desperate situations, and published case series tend to skew positive. The formal randomized trials of rituximab in lupus had more mixed results. Still, the accumulated real-world evidence is strong enough that many lupus treatment guidelines include rituximab as an option for severe or refractory cases.

Rituximab is typically given as two infusions spaced two weeks apart, with each infusion lasting several hours. The B-cell depletion it causes can last for months, so repeat cycles are given only when the disease flares again rather than on a fixed schedule.

Cyclophosphamide for Lupus Nephritis

Cyclophosphamide is an older chemotherapy drug that has been a cornerstone of treatment for severe lupus nephritis since the 1980s. It suppresses the immune system broadly rather than targeting a specific cell type. A landmark controlled trial showed that an extended course of pulse IV cyclophosphamide was more effective than high-dose steroids alone at preserving kidney function, and adding a quarterly maintenance schedule reduced the rate of disease flares.⁸

The downside is that cyclophosphamide carries more side effects than the biologic infusions, including nausea, increased infection risk, and potential harm to fertility, especially at higher cumulative doses. Newer protocols use lower doses and shorter courses to limit these problems. A key trial compared oral mycophenolate with monthly IV cyclophosphamide for induction therapy in lupus nephritis and found them similarly effective, giving doctors and patients more choices.⁹ In practice, cyclophosphamide infusions are now reserved mostly for the initial aggressive phase of kidney disease, after which patients typically switch to a gentler maintenance drug.

How Infusions Help Protect the Kidneys

Lupus nephritis is one of the most serious complications of SLE, and it is the clinical scenario where infusion therapy has made the biggest difference. Belimumab became the first biologic formally approved for lupus nephritis based on the BLISS-LN trial, which found that 43% of patients on belimumab plus standard therapy achieved a primary kidney response at two years, compared to 32% on standard therapy alone. Complete renal responses were also higher, and the risk of a renal-related event or death was cut roughly in half.¹⁰

Obinutuzumab, a newer anti-CD20 drug related to rituximab, is also being studied for lupus nephritis. In the NOBILITY trial, 38% of patients on obinutuzumab achieved a complete kidney response while on a low steroid dose at week 76, compared to 16% on placebo. The gap narrowed somewhat by week 104.¹¹ In pediatric cases that have resisted everything else, doctors have even tried combining rituximab with daratumumab (an anti-CD38 drug that targets long-lived plasma cells) in a single infusion, with promising early results.¹²

Infection Risk and Safety

Any drug that suppresses the immune system raises the question of infection. The British Isles Lupus Assessment Group tracked 274 lupus patients treated with rituximab and found that 30% experienced at least one infection in the first nine months, with respiratory and urinary tract infections being the most common. About 11% had a serious infection. Most infections clustered in the first three months after the infusion, when immune suppression is deepest.¹³

Belimumab and anifrolumab generally carry a lower infection burden than rituximab, partly because they do not wipe out B cells as aggressively. Infusion reactions such as headache, nausea, or rash can occur with any IV biologic, and the first infusion tends to be the riskiest, which is why centers typically run the initial dose slowly and keep you for observation afterward. Cyclophosphamide, being a broader immunosuppressant, also carries meaningful infection risk and requires monitoring of blood counts.

When Your Body Fights the Drug

One underappreciated challenge with biologic infusions is immunogenicity: your immune system can recognize the drug itself as foreign and produce anti-drug antibodies (ADAs). This is ironic, since these drugs are designed to calm the immune system, yet the immune system sometimes responds by attacking the medicine.

Rituximab is particularly prone to this in lupus patients. One study found that about 38% of lupus patients developed ADAs after their first rituximab cycle, compared to zero patients with a different autoimmune condition treated identically.¹⁴ Patients who developed these antibodies had higher disease activity, faster B-cell recovery, and more infusion reactions at retreatment. Over a 36-month follow-up, about three-quarters of lupus patients treated with rituximab tested positive for ADAs at some point, and those who were persistently positive had lower drug levels in their blood and relapsed earlier.¹⁵ Over half of tested patients showed antibodies with genuine neutralizing capacity, meaning the antibodies could directly block the drug from working.¹⁵

This phenomenon has real consequences for treatment decisions. It is one reason some doctors are interested in combining rituximab with belimumab, hoping that belimumab’s BLyS blockade will prevent the resurgence of B cells that produce anti-drug antibodies. However, early trials of this dual-targeting approach have not yet shown clear superiority over monotherapy, and better biomarkers are needed to identify which patients will benefit most from combination strategies.¹⁶

Vaccinations and Timing Around Infusions

Because these drugs suppress parts of the immune system, they can blunt your response to vaccines. The degree varies sharply by drug. Belimumab appears relatively vaccine-friendly: a randomized study found that pneumococcal vaccine responses were essentially the same whether patients were vaccinated before starting belimumab or while already receiving it.¹⁷

Rituximab is a different story. Because it depletes B cells, which are the cells that produce antibodies in response to vaccines, the timing of vaccination matters enormously. After rituximab, the chance of responding to a vaccine is below 20% if you are vaccinated within six months, climbing to roughly 50% by one year out.¹⁸ This means flu shots, pneumonia vaccines, and COVID boosters ideally should be given well before a rituximab infusion or at least several months after. If you are on mycophenolate alongside your infusions, holding that drug briefly around vaccination may improve antibody responses without triggering flares.¹⁹

Pregnancy and Lupus Infusions

Lupus disproportionately affects women of childbearing age, so the question of which infusions are safe during pregnancy comes up often. Biologics like rituximab, belimumab, and abatacept do not significantly cross the placenta until around the 15th week of pregnancy, so they can generally be continued through conception and into early pregnancy. For patients who depend on one of these drugs to stay in remission, the decision about continuing through pregnancy is made on a case-by-case basis, weighing the risks of the drug against the risks of a lupus flare, which itself can be dangerous for both mother and baby.²⁰ Cyclophosphamide, however, is clearly harmful to a developing fetus and is contraindicated in pregnancy.

The Cost of Infusion Therapy

Infusion treatments for lupus are expensive. Patients with moderate-to-severe disease requiring biologic or specialty therapies can face medication costs exceeding $30,000 per year in the United States, and very severe SLE can push annual costs past $68,000 when you factor in all medical expenses. Over a decade, a patient with very severe disease can easily surpass $500,000 in combined medical bills, medications, and lost productivity.²¹ Insurance coverage varies, and many patients rely on manufacturer assistance programs or foundation grants to afford their infusions. The infusion itself also requires clinic time, nursing staff, and sometimes pre-medications, all of which add to the bill.

CAR-T Cell Therapy on the Horizon

The most dramatic development in lupus infusion therapy is the emergence of CAR-T cell treatment. Originally developed for blood cancers, this approach involves removing a patient’s own immune cells, engineering them to target and destroy B cells, and infusing them back. It is a one-time infusion rather than an ongoing regimen, and the early results in lupus have been striking.

A pioneering study in five patients with refractory SLE reported that all five achieved remission within three months. Their disease-activity scores dropped to zero, autoantibodies disappeared, and they were able to stop all lupus medications. Remission was maintained for a median of eight months even after B cells began reappearing, and those new B cells were naive, meaning they did not carry the old self-attacking programming.²² A later study using allogeneic (donor-derived) CAR-T cells in four patients confirmed sustained improvement at three to six months, with resolution of arthritis, alopecia, and vasculitis symptoms.²³

More recently, researchers have tried dual-targeting CAR-T cells that go after both CD19 and BCMA, aiming to eliminate not only regular B cells but also long-lived plasma cells that can sustain autoantibody production. In a phase 1 trial of 15 patients, 80% met criteria for both low disease activity and remission by week 12.²⁴ The treatment was well tolerated, with only mild cytokine-release syndrome (a temporary inflammatory reaction that is expected and manageable).

CAR-T therapy for lupus is still experimental, limited to a handful of medical centers, and extremely costly in its current form. But the possibility of a single infusion replacing years of ongoing immunosuppression has generated enormous excitement. If larger trials confirm the durability of these remissions, CAR-T could fundamentally change how refractory lupus is treated. For now, the standard infusions described above remain the workhorses, and the approval of belimumab in 2011 opened a door that the field has been pushing wider ever since, with over 70 targeted therapies in clinical development.²⁵